FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2558742004> ?p ?o ?g. }

• W2558742004 endingPage "3668" @default.
• W2558742004 startingPage "3668" @default.
• W2558742004 abstract "Abstract Introduction: Asmyeloid leukemia in Down syndrome patients (ML-DS) is known to have higher sensitivity against cytotoxic agents, children with ML-DS are treated with less intensive ML-DS-oriented protocol in recent clinical studies. On the basis of results of previous Japanese trials for ML-DS, we have evaluated an efficacy of the risk-oriented therapy in the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-D05 study. Patients and Methods: Between January 2008 and December 2010, seventy-four patients with newly diagnosed ML-DS from 122 hospitals in Japan were enrolled in this study. All patients received induction chemotherapy consisted of pirarubicin (25 mg/m2/d for 2 days), cytarabine (100 mg/m2/d for 7 days), and etoposide (150 mg/m2/d for 3 days). Patients who achieved complete remission (CR) after initial induction therapy were stratified to the Standard Risk (SR) and received four courses of reduced dose intensification therapy. Patients who did not achieve CR were stratified to the High Risk (HR) and received intensfied therapy consisted of continuous and high-dose cytarabine. Prophylaxis for CNS leukemia was not included throughout the therapy. Results: Out of 74 patients registered in this study, two patients were excluded (one because of uncontrolled cardiac failure, another of non-Down syndrome), and 72 were eligible and were evaluated. Male/Female ratio was 40/32. The median age at diagnosis was 19 months (range, 10 months and 17 years old). Median follow-up period was 3.64 years (range, 0.05 -5.96 years. One patient died of sepsis during initial induction therapy. Sixty-nine patients were stratified to SR and 2 patients to HR. Both of the two HR patients achieved CR but one relapsed. No therapy-related death was observed during intensification therapy. The 3-year event free and overall survival rate was 83.3% ± 4.4% and 87.5% ± 3.9 %, respectively. Age at diagnosis less than 2 years old was significant favorable prognostic factor for relapse (p=0.009). Sex, history of TAM, and chromosomal abnormalities (Normal karyotype or monosomy 7) did not influence the risk of relapse. Conclusion: This study succeeded the previous Japanese strategy with very low-intensive chemotherapy regimen for ML-DS, and despite the dose reduction of chemotherapeutic agents compared to the previous studies, the overall outcome was good and further dose reduction might be possible for specific subgroups. However, considering that most relapse occurred in the SR group defined by morphological treatment response and that relapsed cases are rarely salvageable, more accurate method for identification of the poor prognostic subgroup is needed. This trial is registered with UMIN Clinical Trials Registry (UMIN-CTR, URL: http://www.umin.ac.jp/ctr/index.htm), number UMIN000000989. Disclosures No relevant conflicts of interest to declare." @default.
• W2558742004 created "2016-12-08" @default.
• W2558742004 creator A5001385905 @default.
• W2558742004 creator A5003151415 @default.
• W2558742004 creator A5005186987 @default.
• W2558742004 creator A5016286590 @default.
• W2558742004 creator A5019098042 @default.
• W2558742004 creator A5029932023 @default.
• W2558742004 creator A5030021970 @default.
• W2558742004 creator A5031329064 @default.
• W2558742004 creator A5036019071 @default.
• W2558742004 creator A5038334164 @default.
• W2558742004 creator A5038338410 @default.
• W2558742004 creator A5041204580 @default.
• W2558742004 creator A5042739835 @default.
• W2558742004 creator A5044883471 @default.
• W2558742004 creator A5051701709 @default.
• W2558742004 creator A5064052373 @default.
• W2558742004 creator A5064359506 @default.
• W2558742004 creator A5075108063 @default.
• W2558742004 creator A5079667875 @default.
• W2558742004 creator A5087756926 @default.
• W2558742004 creator A5090382710 @default.
• W2558742004 date "2014-12-06" @default.
• W2558742004 modified "2023-10-07" @default.
• W2558742004 title "Risk-Oriented Therapy for Myeloid Leukemia of Down Syndrome: A Nationwide Prospective Study By the Japanese Pediatric Leukemia / Lymphoma Study Group (JPLSG)" @default.
• W2558742004 doi "https://doi.org/10.1182/blood.v124.21.3668.3668" @default.
• W2558742004 hasPublicationYear "2014" @default.
• W2558742004 type Work @default.
• W2558742004 sameAs 2558742004 @default.
• W2558742004 citedByCount "0" @default.
• W2558742004 crossrefType "journal-article" @default.
• W2558742004 hasAuthorship W2558742004A5001385905 @default.
• W2558742004 hasAuthorship W2558742004A5003151415 @default.
• W2558742004 hasAuthorship W2558742004A5005186987 @default.
• W2558742004 hasAuthorship W2558742004A5016286590 @default.
• W2558742004 hasAuthorship W2558742004A5019098042 @default.
• W2558742004 hasAuthorship W2558742004A5029932023 @default.
• W2558742004 hasAuthorship W2558742004A5030021970 @default.
• W2558742004 hasAuthorship W2558742004A5031329064 @default.
• W2558742004 hasAuthorship W2558742004A5036019071 @default.
• W2558742004 hasAuthorship W2558742004A5038334164 @default.
• W2558742004 hasAuthorship W2558742004A5038338410 @default.
• W2558742004 hasAuthorship W2558742004A5041204580 @default.
• W2558742004 hasAuthorship W2558742004A5042739835 @default.
• W2558742004 hasAuthorship W2558742004A5044883471 @default.
• W2558742004 hasAuthorship W2558742004A5051701709 @default.
• W2558742004 hasAuthorship W2558742004A5064052373 @default.
• W2558742004 hasAuthorship W2558742004A5064359506 @default.
• W2558742004 hasAuthorship W2558742004A5075108063 @default.
• W2558742004 hasAuthorship W2558742004A5079667875 @default.
• W2558742004 hasAuthorship W2558742004A5087756926 @default.
• W2558742004 hasAuthorship W2558742004A5090382710 @default.
• W2558742004 hasConcept C126322002 @default.
• W2558742004 hasConcept C141071460 @default.
• W2558742004 hasConcept C187212893 @default.
• W2558742004 hasConcept C2776694085 @default.
• W2558742004 hasConcept C2778041864 @default.
• W2558742004 hasConcept C2778119113 @default.
• W2558742004 hasConcept C2778461978 @default.
• W2558742004 hasConcept C2778729363 @default.
• W2558742004 hasConcept C71924100 @default.
• W2558742004 hasConcept C90924648 @default.
• W2558742004 hasConceptScore W2558742004C126322002 @default.
• W2558742004 hasConceptScore W2558742004C141071460 @default.
• W2558742004 hasConceptScore W2558742004C187212893 @default.
• W2558742004 hasConceptScore W2558742004C2776694085 @default.
• W2558742004 hasConceptScore W2558742004C2778041864 @default.
• W2558742004 hasConceptScore W2558742004C2778119113 @default.
• W2558742004 hasConceptScore W2558742004C2778461978 @default.
• W2558742004 hasConceptScore W2558742004C2778729363 @default.
• W2558742004 hasConceptScore W2558742004C71924100 @default.
• W2558742004 hasConceptScore W2558742004C90924648 @default.
• W2558742004 hasIssue "21" @default.
• W2558742004 hasLocation W25587420041 @default.
• W2558742004 hasOpenAccess W2558742004 @default.
• W2558742004 hasPrimaryLocation W25587420041 @default.
• W2558742004 hasRelatedWork W137333672 @default.
• W2558742004 hasRelatedWork W2018395272 @default.
• W2558742004 hasRelatedWork W2023291141 @default.
• W2558742004 hasRelatedWork W2030418865 @default.
• W2558742004 hasRelatedWork W2066447718 @default.
• W2558742004 hasRelatedWork W2073730465 @default.
• W2558742004 hasRelatedWork W2186865501 @default.
• W2558742004 hasRelatedWork W2339313313 @default.
• W2558742004 hasRelatedWork W4229791987 @default.
• W2558742004 hasRelatedWork W4247120321 @default.
• W2558742004 hasVolume "124" @default.
• W2558742004 isParatext "false" @default.
• W2558742004 isRetracted "false" @default.
• W2558742004 magId "2558742004" @default.
• W2558742004 workType "article" @default.